小乳头括约肌切开术治疗胰腺分裂伴特发性急性胰腺炎:一项随机临床试验
这项多中心、假手术对照、双盲随机临床试验纳入148例有2次及以上急性胰腺炎发作且存在胰腺分裂的成人,比较内镜逆行胰胆管造影(ERCP)联合小乳头括约肌切开术与假ERCP的效果。主要终点为随机分组30天后急性胰腺炎的发生,结果显示两组无显著差异(调整后风险比0.83,95%CI 0.49-1.41)。结论认为该手术不能降低急性胰腺炎复发或相关后遗症的风险。
要点
- 在胰腺分裂伴不明原因复发性急性胰腺炎成人中,ERCP联合小乳头括约肌切开术未显著降低30天后急性胰腺炎发生风险。
- 小乳头括约肌切开术组与假ERCP组的调整后风险比为0.83(95%CI 0.49-1.41)。
- 随机分组30天内急性胰腺炎不良事件在小乳头括约肌切开术组为14.7%,假ERCP组为8.2%。
核心结论
- 在不明原因复发性急性胰腺炎合并胰腺分裂的患者中,ERCP联合小乳头括约肌切开术不能降低再次发生急性胰腺炎或相关后遗症的风险。
研究设计与样本
- 多中心、假手术对照、双盲随机临床试验,于2018年9月1日至2024年8月30日在美国和加拿大的21个转诊中心进行,末次随访于2025年2月15日。
- 纳入2次及以上急性胰腺炎发作且存在胰腺分裂的成人,排除其他病因或合并慢性钙化性胰腺炎者,共随机148例(平均年龄54岁,标准差19.5;女性68.2%;非西班牙裔或拉丁裔95.3%,白人87.2%;平均终生急性胰腺炎发作次数3次,标准差2;平均胰管直径2.2 mm,标准差1.3),按1:1随机接受ERCP联合小乳头括约肌切开术或假ERCP,中位随访34个月(IQR 21.7-45.7个月)。
主要发现
- 主要终点随机分组30天后急性胰腺炎发生:小乳头括约肌切开术组75例中26例(34.7%)发生,假ERCP组73例中32例(43.8%)发生,调整后风险比0.83(95%CI 0.49-1.41)。
- 急性复发性胰腺炎发作频率的发病率比:小乳头括约肌切开术组0.25(95%CI 0.18-0.34),假ERCP组0.30(95%CI 0.23-0.41)。
- 慢性钙化性胰腺炎发生率:小乳头括约肌切开术组4.0% vs 假ERCP组2.7%,风险差0.01(95%CI -0.05至0.07)。
- 糖尿病发生率:小乳头括约肌切开术组15.8% vs 假ERCP组12.8%,风险差0.03(95%CI -0.13至0.19)。
- 外分泌胰腺功能障碍发生率:小乳头括约肌切开术组7.7% vs 假ERCP组17.2%,风险差-0.10(95%CI -0.27至0.08)。
关键数值与推荐
- 主要终点随机分组30天后急性胰腺炎发生:小乳头括约肌切开术组34.7% vs 假ERCP组43.8%,调整后风险比0.83(95%CI 0.49-1.41)。
- 急性复发性胰腺炎发作频率的发病率比:小乳头括约肌切开术组0.25(95%CI 0.18-0.34)vs 假ERCP组0.30(95%CI 0.23-0.41)。
- 慢性钙化性胰腺炎发生率:小乳头括约肌切开术组4.0% vs 假ERCP组2.7%,风险差0.01(95%CI -0.05至0.07)。
- 糖尿病发生率:小乳头括约肌切开术组15.8% vs 假ERCP组12.8%,风险差0.03(95%CI -0.13至0.19)。
- 外分泌胰腺功能障碍发生率:小乳头括约肌切开术组7.7% vs 假ERCP组17.2%,风险差-0.10(95%CI -0.27至0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes. Even though this endoscopic procedure is widely used in practice, clinical trials are lacking. OBJECTIVE: To determine whether ERCP with minor papillotomy reduces the risk of acute pancreatitis among adults with unexplained acute recurrent pancreatitis and pancreas divisum. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, sham-controlled, double-blind randomized clinical trial enrolled adults with 2 or more episodes of acute pancreatitis and pancreas divisum. Adults with other etiologies for acute pancreatitis or concomitant chronic calcific pancreatitis were excluded. The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada. Last follow-up occurred on February 15, 2025. INTERVENTION: Participants were randomized in a 1:1 ratio to ERCP with minor papillotomy or sham ERCP. MAIN OUTCOMES AND MEASURES: The primary outcome was development of acute pancreatitis more than 30 days after randomization as a time-to-event outcome. The secondary outcomes included acute pancreatitis episode frequency and development of chronic calcific pancreatitis, diabetes, and exocrine pancreatic dysfunction. RESULTS: A total of 148 participants were randomized (mean age, 54 [SD, 19.5] years; 68.2% female; 95.3% non-Hispanic or Latino and 87.2% White; mean lifetime acute pancreatitis episodes, 3 [SD, 2]; mean duct diameter, 2.2 [SD, 1.3] mm) and followed up for a median of 34 months (IQR, 21.7-45.7 months). Of the 75 participants in the ERCP with minor papillotomy group, 26 (34.7%) developed acute pancreatitis compared with 32 of 73 participants (43.8%) in the sham ERCP group (adjusted hazard ratio, 0.83 [95% CI, 0.49 to 1.41]). The incidence rate ratio for acute recurrent pancreatitis episode frequency was 0.25 (95% CI, 0.18 to 0.34) in the ERCP with minor papillotomy group vs 0.30 (95% CI, 0.23 to 0.41) in the sham ERCP group. There were no between-group differences in frequency and incidence of chronic calcific pancreatitis (4.0% in the ERCP with minor papillotomy group vs 2.7% in the sham ERCP group; risk difference [RD], 0.01 [95% CI, -0.05 to 0.07]), diabetes (15.8% vs 12.8%, respectively; RD, 0.03 [95% CI, -0.13 to 0.19]), and exocrine pancreatic dysfunction (7.7% vs 17.2%; RD, -0.10 [95% CI, -0.27 to 0.08]). The adverse event of acute pancreatitis within 30 days of randomization occurred more frequently in the ERCP with minor papillotomy group (14.7%) vs the sham ERCP group (8.2%) (RD, 0.06 [95% CI, -0.04 to 0.17]). CONCLUSIONS AND RELEVANCE: Among patients with unexplained acute recurrent pancreatitis and pancreas divisum, ERCP with minor papillotomy does not reduce the risk of another episode of acute pancreatitis or related sequelae. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03609944.
引用
- Coté GA, Durkalski-Mauldin V, Fogel EL, et al. Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum: A Randomized Clinical Trial. JAMA. 2026. PMID: 41533371. doi:10.1001/jama.2025.23988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。